Home / Market News / $LGND
fiscal.ai Corporate Catalyst Impact 65/100 ● positive

RBC Raises Price Target on Ligand Pharmaceuticals to $357 From $345

Oct 30, 2026, 1:36 PM UTC · Primary ticker $LGND

RBC Capital Markets has increased its price target for Ligand Pharmaceuticals to $357 from $345, while reiterating an Outperform rating. This adjustment follows the company's strong Q3 2026 financial results and an upward revision to its 2026 adjusted EPS guidance, signaling positive analyst sentiment and improved financial outlook.

RBC Capital Markets raised its price target for Ligand Pharmaceuticals (LGND) to $357 from $345 and maintained an Outperform rating. This positive revision is a direct consequence of the company's robust third-quarter 2026 financial performance and, crucially, an increase in its 2026 adjusted EPS guidance. This indicates that analysts believe the company's future earnings potential has improved, which is a positive signal for investors. The short-term implication is likely a positive sentiment boost for LGND stock, potentially leading to upward price movement as investors react to the analyst upgrade and improved guidance. Long-term, sustained strong financial performance and continued positive analyst coverage could support further stock appreciation. The key opportunity for traders is to capitalize on the immediate positive reaction to the upgraded guidance and price target.

$LGND positive Increased price target and maintained Outperform rating
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.